Literature DB >> 18991746

2-Arylbenzimidazoles as antiviral and antiproliferative agents. Part 1.

G Vitale1, A Carta, M Loriga, G Paglietti, P La Colla, B Busonera, D Collu, R Loddo.   

Abstract

Being involved in an anti-Flaviviridae Project, and because of the role played by benzimidazole derivatives as promising inhibitors of the HCV helicase and RNA polymerase, as well as of the Zn finger transcription factor, we synthesized a new series of 2-arylbenzimidazoles and evaluated them for antiviral activity, as well as for antiproliferative activity. Compounds were tested in cell-based assays against viruses representative of: i) two of the three genera of the Flaviviridae family, i.e. Flaviviruses and Pestiviruses; ii) other RNA virus families, such as Retroviridae, Picornaviridae, Paramyxoviridae, Rhabdoviridae and Reoviridae; iii) two DNA virus families (Herpesviridae and Poxviridae). Compounds 15, 28 and 29 resulted moderately active only against Yellow Fever Virus (a Flavivirus) (range 6-27 microM), whereas none of the title benzimidazoles showed any antiviral activity at concentrations not cytotoxic for the resting cell monolayers. Compounds were also tested for antiproliferative activity against a panel of exponentially growing cell lines derived from human haematological and solid tumors. Several new benzimidazoles turned out active. Among them, compound 27 was the most potent against human haematologic and solid tumor cells and turned out to be as potent as Etoposide and more potent than 6-mercaptopurine (6-MP), used as reference antitumor agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991746     DOI: 10.2174/157340608786241990

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  1 in total

1.  Ethyl 2-(4-bromo-phen-yl)-1-sec-butyl-1H-benzimidazole-5-carboxyl-ate.

Authors:  Natarajan Arumugam; Nurziana Ngah; Shafida Abd Hamid; Aisyah Saad Abdul Rahim
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-11-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.